Sign In
Buy MRNA
$51.59
+2.53 (+5.16%)
At Close: Jun 04, 2026
MRNA, PFE Stocks Jump Despite FDA's Stricter Standards for COVID-19 Shots
09:41am, Wednesday, 21'st May 2025
Though the new FDA rules limit access to COVID-19 booster vaccines, the commitment to high-risk groups lifts Moderna, Pfizer and BioNTech stocks.
Moderna withdraws application for COVID-flu combination vaccine
07:12am, Wednesday, 21'st May 2025
Moderna said on Wednesday it had withdrawn the pending application for its flu and COVID combination vaccine candidate for adults aged 50 years and older.
Moderna Provides Update on BLA Submission for Combination Vaccine Against Influenza and COVID-19
07:00am, Wednesday, 21'st May 2025
CAMBRIDGE, MA / ACCESS Newswire / May 21, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdra
Moderna shares surge as new FDA vaccine framework eases investor concerns
01:09pm, Tuesday, 20'th May 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares jumped more than 6.5% on Tuesday after the US Food and Drug Administration unveiled a new framework for COVID-19 vaccine approvals that analysts said largely
The FDA Is Limiting Covid Shots. But Moderna, Vaccine Stocks Jumped.
12:22pm, Tuesday, 20'th May 2025
The FDA said Tuesday it will limit future Covid vaccines to older and at-risk Americans. The move buoyed Moderna, BioNTech and Novavax.
Top Stock Movers Now: Viking, Moderna, Uber Technologies, and More
12:10pm, Tuesday, 20'th May 2025
U.S. equities were lower at midday, dragged by tech and travel stocks. The Dow Jones Industrial Average, S&P 500, and Nasdaq were all lower.
Moderna: After A Crash From $500 To $25, I'm Buying This "Call Option" On Pandemics And Cancer
09:43am, Tuesday, 20'th May 2025
Moderna's share price has collapsed from $500 to $25, but I believe the selloff is overdone, and the stock is deeply oversold. Short squeeze potential, a robust pipeline, and long-term mRNA/AI opportu
S&P500 and Nasdaq Index: Consumer Data Sinks Sentiment, Super Micro, Moderna Rally
12:00pm, Friday, 16'th May 2025
S&P 500 and Nasdaq edge higher mid-session as weak sentiment data tempers gains. Traders assess inflation risks and tariff uncertainty.
1 Beaten-Down Stock to Buy Right Now, and 1 to Avoid
05:30am, Friday, 16'th May 2025
Equity markets are full of bargains -- stocks that have performed terribly in recent months, whether due to trade-related marketwide issues or company-specific troubles, but could bounce back once thi
Cautious? Risky? Our Volatility Scorecard Can Help
11:08am, Tuesday, 13'th May 2025
Subscribers to Chart of the Week received this commentary on Sunday, May 11.
Why Moderna Merged Its Tech and HR Departments
07:00am, Monday, 12'th May 2025
The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the growing capabilities of AI and other tech.
Moderna to Present at Upcoming Bernstein's 41st Annual Strategic Decisions Conference (SDC) on May 29, 2025
07:00am, Thursday, 08'th May 2025
CAMBRIDGE, MA / ACCESS Newswire / May 8, 2025 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference: Bernstein's 41st Annual Strategic Decision
New vaccine chief rocks pharmaceutical stocks
11:13am, Wednesday, 07'th May 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Moderna Sharpens Pipeline Focus as COVID-19 Vaccine Demand Ebbs in Q1
10:55am, Tuesday, 06'th May 2025
Moderna plans to launch 10 new marketed products over the next three years, aiming to diversify a revenue base, which is still heavily reliant on COVID-19 vaccine sales.
Moderna faces long-term threat from NIH's universal vaccine initiative, Jefferies says
01:53pm, Friday, 02'nd May 2025
Moderna Inc (NASDAQ:MRNA, ETR:0QF) could face a longer-term threat from a newly announced US government initiative to develop universal vaccines for pandemic-prone viruses, analysts at Jefferies said
